| Collantes, et al., 20024 (n = 445) | Bombardier, et al., 20003 (n = 8,076) | Emery, et al., 19992 (n = 665) | Simon, et al., 19991 (n = 460) | Simon, et al., 19991 (n = 465) |
| Etoricoxib (Arcoxia),* 90 mg once daily, versus naproxen (Naprosyn), 500 mg two times daily | Rofecoxib (Vioxx), 50 mg once daily, versus naproxen, 500 mg two times daily | Celecoxib (Celebrex), 200 mg two times daily, versus diclofenac SR (Voltaren SR), 75 mg two times daily | Celecoxib, 200 mg two times daily, versus naproxen, 500 mg two times daily | Celecoxib, 100 mg two times daily, versus naproxen, 500 mg two times daily |
| Number of tender joints | – | Not assessed | – | – | – |
| Number of swollen joints | – | Not assessed | – | – | – |
| Patient's global assessment of pain | – | Not assessed | – | – | – |
| Functional disability | – | – | – | – | – |
| Patient's global assessment of disease activity | – | – | – | Better with celecoxib | – |
| Physician's global assessment of disease activity | – | – | – | Better with celecoxib | – |
| Percentage of patients meeting ACR-20 criteria† | – | Not assessed | – | – | – |
| Withdrawals for lack of efficacy | – | – | – | – | – |